PhRMA: Pharmaceutical Companies Developing 27 New Drugs for Parkinson's Disease

According to a new report by the Pharmaceutical Research and Manufacturers Association (PhRMA), there are nearly 450 medicines for neurological disorders currently in research and development, including 27 new drugs for Parkinson’s disease. These drugs are either in human clinical trials or under review by the Food and Drug Administration.

The report highlights the following medicines as some of the most promising.

  • A medicine that prompts the immune system to protect neurons affected by amyotrophic lateral sclerosis.
  • Gene therapy for the treatment of Alzheimer’s disease.
  • Gene therapy to reverse the effects of Parkinson’s disease.

This is good news for the millions of people affected by neurological disorders such as Alzheimer's, epilepsy, multiple sclerosis, and Parkinson’s. While progress is being made, this report highlights the ongoing need to advocate for more funding for medical research to make more of these medicines possible.

Read the full report.


Date originally posted: August 2, 2013.